The global cancer biomarker market size was valued at USD 38.5 billion in 2025 and is projected to grow from USD 43.43 billion in 2026 to USD 113.83 billion by 2034, registering a CAGR of 12.8% during the forecast period from 2026 to 2034. North America dominated the cancer biomarker market with a market share of 41.2% in 2025.
Cancer biomarkers are biological molecules or measurable indicators found in blood, tissue, urine, or other body fluids that provide information about the presence, progression, or response to treatment of cancer. They include genetic mutations, proteins, enzymes, and other molecular signatures used for early detection, diagnosis, prognosis, treatment selection, and monitoring therapeutic outcomes, enabling more precise and personalized cancer care.
Download a Free Sample To learn more about this report,
Integration of Artificial Intelligence in Cancer Biomarker Discovery
The growing volume and complexity of genomic, proteomic, imaging, and clinical data is encouraging researchers to use artificial intelligence for identifying patterns linked to cancer development, diagnosis, and treatment response. This transition is making biomarker discovery more data-driven by helping researchers analyze high-dimensional datasets and identify potential molecular signatures that may be difficult to detect through conventional analysis. For example, the National Cancer Institute uses AI and machine learning to analyze genomic data for biomarker discovery, including identifying biomarkers associated with immunotherapy and detecting potential driver genes.
Adoption of Liquid Biopsy for Non-Invasive Cancer Detection
The need for less invasive approaches to obtain cancer-related molecular information is encouraging the use of liquid biopsy based on blood-derived cell-free DNA and circulating tumor DNA. This transition is expanding biomarker testing beyond tissue samples and supports applications such as mutation detection, treatment selection, and monitoring of molecular residual disease. For example, the FDA has approved liquid biopsy tests such as FoundationOne Liquid CDx for detecting mutations in circulating cell-free DNA to help identify patients who may benefit from specific cancer treatments.
Early Cancer Diagnosis and Biomarker-Based Patient Stratification Drive Market
The need for earlier cancer detection creates demand for biomarkers that can help identify disease-related biological changes before advanced symptoms appear. Healthcare providers use biomarker testing to support diagnosis, assess disease characteristics, and guide further clinical evaluation. For example, prostate-specific antigen (PSA) testing can help assess prostate cancer risk and determine whether additional diagnostic evaluation is needed. This clinical need supports the use of cancer biomarker tests across hospitals, diagnostic laboratories, and oncology centers.
The need to match treatments with patient-specific disease characteristics creates demand for biomarkers that support patient stratification. The National Cancer Institute explains that biomarker testing can help doctors select treatments that are more likely to work for patients with specific genetic or molecular characteristics. For example, HER2 testing helps identify breast cancer patients who may be candidates for HER2-targeted therapies such as trastuzumab. This treatment-selection requirement supports the use of biomarker testing in oncology practice and clinical drug development.
Regulatory Requirements and Skilled Workforce Limit Market Expansion
Complex regulatory requirements for cancer biomarker tests can increase the evidence, validation, and documentation needed before commercialization. FDA guidance indicates that IVD evaluations can involve analytical performance, clinical sensitivity and specificity, and clinical validity, while companion diagnostics may require additional regulatory considerations. These requirements can increase development time and costs, delay product launches, and slow the adoption of cancer biomarker technologies.
Limited availability of skilled professionals in molecular diagnostics, genomics, pathology, bioinformatics, and clinical interpretation can restrict the effective use of cancer biomarker technologies. Specialized expertise is needed to perform advanced testing, interpret complex biomarker results, and integrate findings into clinical decisions. This workforce gap can reduce testing capacity and slow the growth of the cancer biomarker market.
Companion Diagnostics and Pharmaceutical Biomarker Partnerships Offers Growth Opportunities
Diagnostic companies, oncology laboratories, and pharmaceutical firms can develop tests that identify patients eligible for specific targeted treatments. The FDA’s authorized-device list includes multiple oncology companion diagnostics, including Guardant360 CDx and FoundationOne CDx for specific cancer biomarkers, creating revenue through diagnostic kits, testing services, and drug-diagnostic partnerships.Biomarker developers, pharmaceutical companies, and diagnostic laboratories can collaborate on biomarker validation, clinical development, and patient-selection strategies. The FDA reported 12 companion-diagnostic approvals among 18 oncology IVD authorizations in 2022, highlighting the role of diagnostic–drug co-development. Such partnerships create revenue through licensing, testing services, and co-development agreements.
Tumor Variability and Clinical Sample Limitations Hinders Growth
Genetic and molecular differences between tumors can cause the same biomarker to perform differently across patients or cancer subtypes. The National Cancer Institute notes that differences can occur both between tumors in different patients and among cancer cells within the same tumor, creating challenges for accurate diagnosis and treatment prediction. This variability can require additional validation and patient stratification, increasing development timelines and costs.
Cancer biomarker development depends on well-characterized tumor tissue, blood samples, and associated clinical data from diverse patient populations. The National Cancer Institute identifies the lack of high-quality research biospecimens as a major roadblock to cancer research and notes that differences in collection, processing, storage, and associated data can affect research reproducibility. Limited access to consistent, well-annotated specimens can slow assay development and clinical validation, delaying product commercialization.
The breast cancer segment accounted for a 17.9% share in 2025 and is expected to grow at a CAGR of 13.4% during the forecast period 2026-2034, driven by the high prevalence of breast cancer, increasing demand for early detection, and growing adoption of biomarker-based diagnosis and personalized treatment approaches. the rising use of molecular and genetic biomarkers for disease monitoring and treatment selection further strengthens the segment’s dominant position in the cancer biomarker market.
The lung cancer segment supports biomarker applications for early diagnosis, molecular profiling, and targeted therapy, while the prostate cancer segment contributes through biomarker-based screening and treatment monitoring. the melanoma segment benefits from increasing use of biomarkers for diagnosis and immunotherapy selection, while the thyroid cancer segment supports molecular testing and disease classification. the kidney cancer segment contributes through biomarker-based diagnosis and treatment monitoring, while the bladder cancer segment supports molecular testing and recurrence monitoring. the leukemia segment benefits from biomarkers used for disease classification, prognosis, and treatment selection, while the non-Hodgkin's lymphoma segment supports biomarker applications in diagnosis and personalized therapy. the colorectal cancer segment contributes through biomarkers for early detection, molecular profiling, and targeted treatment, while the other cancer types segment includes biomarker applications across additional malignancies.
Request Customizationto receive a tailored report.
The diagnostics segment accounted for a share of 36.9% in 2025, owing to the widespread use of cancer biomarkers for early disease detection, accurate diagnosis, disease classification, and treatment monitoring. the increasing demand for precise diagnostic methods and growing adoption of biomarker-based testing further strengthen the segment’s dominant position in the cancer biomarker market.
The personalized medicines segment is expected to grow at a CAGR of 14.1% during the forecast period, driven by increasing adoption of precision oncology, growing use of biomarkers for patient stratification, and rising demand for targeted therapies based on individual disease characteristics. the drug discovery & development segment supports biomarker use in identifying therapeutic targets, evaluating drug efficacy, and accelerating clinical development, while the other applications segment includes additional uses of cancer biomarkers across research, prognosis, and treatment monitoring.
Speak to an Analystto discuss market opportunities.
The North America cancer biomarker market accounted for the largest regional share of 41.2% in 2025, driven by advanced cancer diagnostic infrastructure, high adoption of biomarker-based testing, and strong investment in precision oncology research. The U.S. cancer biomarker market is supported by the U.S. National Cancer Institute’s ongoing biomarker development and validation initiatives, including a 2026-funded project focused on accelerating cancer biomarker development through improved statistical methods for phase III/IV studies. The National Cancer Institute also continues to develop and validate biomarker assays for precision oncology and treatment-response assessment.
The Canada cancer biomarker market is supported by expanding precision oncology capabilities, with the federal government providing $80 million over four years to the Marathon of Hope Cancer Centres Network to expand its database and collaboration network and support the use of precision medicine in real time to inform cancer treatment. Canadian clinical research is also evaluating circulating tumor DNA as a predictive biomarker for treatment response in colon cancer, supporting the development and application of biomarker-based cancer care.
Unlock Regional Insightsto access country-level data, & regional trends.
The Asia Pacific cancer biomarker market is expected to grow at a CAGR of 14.6%, showcasing the fastest-growing regional market, driven by rising cancer incidence, expanding healthcare infrastructure, and increasing adoption of advanced diagnostic and precision medicine technologies. In Japan, the Japan Agency for Medical Research and Development selected 2026 research projects specifically focused on cancer biomarkers, including the development of a highly sensitive and accurate cancer marker based on fibronectin glycosylation and biomarkers using multi-omics data and ctDNA testing for colorectal cancer. These projects are part of Japan’s next-generation cancer medicine research program and support continued development of biomarker-based cancer diagnosis and precision medicine.
In China, the National Medical Products Administration initiated a 2026 national standard project for quantitative detection kits for tumor markers using labeled immunoassay methods. Announced in August 2026 with an 18-month development period, the project establishes standardized technical requirements for tumor-marker testing and supports the development and adoption of cancer biomarker diagnostic products. In South Korea, the K-Health MIRAE Initiative and National Cancer Center are advancing Project CANDI, which aims to develop highly sensitive and accessible early-detection methods for the 10 most prevalent cancers in the Korean population, targeting 90% sensitivity and 95% specificity while expanding cancer biomarker discovery and technologies for analyzing trace biomarkers in early-stage cancer. In India, the Department of Biotechnology and associated research ecosystem are advancing AI-enabled and molecular approaches for cancer diagnosis, while in August 2026, the Ministry of Science & Technology reported an AI framework capable of identifying distinct cancer stem-like cell states from thousands of patient samples, supporting improved cancer detection and precision-medicine applications.
The Europe cancer biomarker market accounted for a regional share of 27.4% in 2025, supported by strong cancer research capabilities, growing adoption of molecular diagnostics, and increasing demand for personalized cancer treatment. In the U.K. cancer biomarker market, England’s National Cancer Plan states that every cancer patient who would benefit from genomic testing should receive it within a clinically relevant timeframe. From April 2026, new contracts for seven NHS Genomic Medicine Service Lead Providers are expanding cancer genomic testing to new targets, while circulating tumour DNA (ctDNA) testing for eligible non-small-cell lung cancer patients has been available through the National Genomic Test Directory since May 2025, supporting wider adoption of cancer biomarkers.
In the Germany cancer biomarker market, the Federal Ministry of Health is advancing genomeDE, a nationwide platform intended to enable broader clinical use of genome sequencing for oncological diseases and improve diagnosis and personalized treatment selection. In addition, the BMG-funded CanConnect project is combining cancer-registry and diagnostic datasets for AI-based biomarker detection, with the project running through October 2026, supporting the development of data-driven cancer biomarker applications. Meanwhile, the France cancer biomarker market is supported by the France Medicine Genomics 2025 program, which has established nationwide high-throughput genomic infrastructure for diagnosis and therapeutic monitoring. By January 2025, approximately 5,500 cancer patients had received genome-sequencing results, with 89% having a tumor genetic variant of interest identified that could inform a potential treatment strategy, supporting the expanding role of genomic biomarkers.
The Middle East and Africa cancer biomarker market is expected to grow at a CAGR of 10.7%, supported by improving diagnostic infrastructure, rising awareness of early cancer detection, and increasing investments in advanced healthcare technologies. The UAE cancer biomarker market is expected to benefit from Abu Dhabi’s continued expansion of precision oncology and genomic medicine, with the Department of Health – Abu Dhabi reporting in 2026 that its healthcare research priorities include omics and precision medicine as well as cancer diagnostics and therapeutics, while its Abu Dhabi Biobank connects biological samples with genomic and clinical data to support earlier detection and more personalized care.
The Africa cancer biomarker market is expected to benefit from growing adoption of precision medicine and genomics, with the World Health Assembly endorsing a 2026 resolution calling for stronger national and regional capacities in laboratory and diagnostic infrastructure, genomic databases, and related technologies, including for cancer control, while Africa CDC’s Strategic Advisory Group on Genomics is advancing continental capacity in human genomics, clinical genetics, and precision medicine.
The cancer biomarker market is moderately fragmented, with biotechnology companies, pharmaceutical companies, diagnostic companies, molecular diagnostics providers, research institutions, clinical laboratory service providers, and specialized biomarker technology companies competing across cancer diagnostics, personalized medicine, drug development, and clinical research applications. Established players compete primarily on biomarker discovery capabilities, diagnostic accuracy, technological expertise, clinical validation, research and development, regulatory compliance, product portfolios, data analytics capabilities, strategic partnerships, and global distribution networks, with leading players such as Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Illumina, Inc., QIAGEN N.V., and Abbott Laboratories estimated to account for approximately 50% of the global market based on their product portfolios, technological capabilities, geographic presence, and competitive positioning.
Emerging and regional players within the cancer biomarker market ecosystem compete through cost-effective testing solutions, specialized biomarker platforms, innovative detection technologies, customized services, targeted applications, flexible research capabilities, localized support, and rapid product development to address specific oncology requirements and strengthen their market presence. These players also focus on developing application-specific biomarker solutions, improving detection accuracy, and expanding specialized testing capabilities to differentiate their offerings and broaden their market reach.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
Organ Preservation Market Size, Share, Growth, Analysis, Report, 2034
Bacteriophage Market Size, Share, Growth, Analysis, 2034
Epigenetics Market Size, Share, Growth, Analysis, Report, 2034
Biobanking Market Size, Share, Growth, 2034
Cell Therapy Manufacturing Market Size, Share, Growth, 2034
Clinical Oncology Next Generation Sequencing Market Size, 2034
We are featured on:
sales@straitsresearch.com